REYON PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,620 KRW | -1.09% |
|
+4.69% | -17.65% |
| Sales 2022 | 154B 112M | Sales 2023 | 151B 110M | Capitalization | 303B 221M |
|---|---|---|---|---|---|
| Net income 2022 | 7.43B 5.42M | Net income 2023 | 3.58B 2.61M | EV / Sales 2022 | 3.63 x |
| Net Debt 2022 | 174B 127M | Net Debt 2023 | 201B 146M | EV / Sales 2023 | 3.34 x |
| P/E ratio 2022 |
53.2
x | P/E ratio 2023 |
84.8
x | Employees | 463 |
| Yield 2022 |
0.69% | Yield 2023 |
-
| Free-Float | 42.72% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.09% | ||
| 1 week | +4.69% | ||
| Current month | -10.69% | ||
| 1 month | -15.51% | ||
| 3 months | -12.80% | ||
| 6 months | -7.35% | ||
| Current year | -17.65% |
1 week
13 060.00
13 950.00
1 month
12 840.0016 310.00
Current year
12 840.0017 150.00
1 year
12 840.0019 320.00
3 years
12 840.0077 700.00
5 years
6 794.1277 700.00
10 years
6 794.1277 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Soon-Ok Jeong
CEO | Chief Executive Officer | 73 | - |
Yong-Hwan Yoo
CEO | Chief Executive Officer | 50 | - |
Ju-Won Cho
SAM | Sales & Marketing | 54 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong-Hwan Yoo
CEO | Chief Executive Officer | 50 | - |
Joong-Hyeop Kim
BRD | Director/Board Member | 80 | - |
Soon-Ok Jeong
CEO | Chief Executive Officer | 73 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 13,620 | -1.09% | 16 366 |
| 24-04-24 | 13,770 | -0.07% | 12,849 |
| 24-04-23 | 13,780 | +3.30% | 46,948 |
| 24-04-22 | 13,340 | +1.14% | 14,313 |
| 24-04-19 | 13,190 | -1.42% | 24,782 |
End-of-day quote Korea S.E., April 24, 2024
More quotes
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -17.65% | 184M | |
| +18.59% | 22.25B | |
| +13.49% | 14.39B | |
| +12.83% | 13.55B | |
| +38.02% | 11.27B | |
| -9.80% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.29% | 5.01B | |
| -5.36% | 4.51B |
- Stock Market
- Equities
- A102460 Stock
